Home / Publication / A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

論文

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Author(s): Thijs J. Zweers, Jos Lommerse, Eline van Maanen, Manash S. Chatterjee

Year: 2024年10月22日

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

オンデマンド・ウェビナー

トランスレーショナル開発における中和ADA効果の薬物動態モデリング

ウェビナー

CERTAINTY 2025: The power of Model-Informed Drug Development

ブログ

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

ウェビナー

Powered by Translations.com GlobalLink Web Software

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

トランスレーショナル開発における中和ADA効果の薬物動態モデリング

CERTAINTY 2025: The power of Model-Informed Drug Development

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

メルマガ登録

クイックアクセス

ソリューション

お問合せ